Cancer drug collaborations are hot

Two years ago Merck and AstraZeneca grabbed the attention of the R&D world with their unusual collaboration pact combining two early-stage cancer treatments into a one-two punch. But their partnership is now part of the regular playbook for developers active in the cancer field. Specialists want a "magic shotgun loaded with pellets aimed at multiple targets in multiple pathways," not just a magic bullet, oncologist George Sledge tells Bloomberg Businessweek. And biopharma companies understand that when longtime rivals collaborate, they can advance drugs that do a much better job at extending the lives of patients. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.